If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSupreme Plc Regulatory News (SUP)

Share Price Information for Supreme Plc (SUP)

Share Price is delayed by 15 minutes
Get Live Data
142.50    0.00 (0.00%)
Bid:
141.00
Ask:
144.00
Spread: 3.00 (2.128%)
Market Cap: £165.42m
SUP Live PriceLast checked at - London Stock Exchange

Intraday Supreme Plc Share Chart

Director/PDMR Shareholding

10 Mar 2021 07:00

RNS Number : 7096R
Supreme PLC
10 March 2021
 

10 March 2021

Supreme plc

("Supreme" or the "Company" or the "Group")

Company Share Option Plan 2021, Unapproved Share Option Scheme 2021

&

Grant of Awards to Directors

 

Supreme plc (AIM: SUP), a leading manufacturer, supplier and brand owner of fast-moving consumer products announces the launch of its Company Share Option Plan ("CSOP") and its Unapproved Share Option Scheme for 2021 and the grant of options to Directors.

Company Share Option Plan 2021 ("CSOP") and Unapproved Share Option Scheme 2021 ("Unapproved Scheme")

Under the tax-advantaged CSOP a limited number of eligible employees have been granted options to subscribe for ordinary shares in the Company of 10p each ("Shares"), with an exercise price of 174 pence per Share equal to the closing middle market price on 15 February 2021. The options were granted on 16 February 2021 and will be exercisable by the holder at any time between the third and tenth anniversaries of the date of the grant. Upon exercise, the relevant Shares will be allotted and further announcements will be made regarding this in due course. Some of those employees have been granted additional options on the same basis under the Unapproved Scheme to the extent that the total number of options granted to them exceeded the maximum number permitted to be granted under the CSOP by HMRC rules.

23 employees have been granted options under the CSOP over a total of 206,886 Shares and 4 employees have been granted options under the Unapproved Scheme over a total of 94,825 Shares, being in aggregate 301,711 Shares representing in total 0.26% of the Company's issued share capital.

Grant of options to Directors

As outlined in the Company's Admission Document, dated 27 January 2021, the Company has now made the following grants to Sandy Chadha and Suzanne Smith ("Director Options"). These were made yesterday under the Unapproved Scheme.

Options to subscribe for a total of 5,825,000 Shares at nominal value were granted to Sandy Chadha in two equal tranches each equating to 2.5 per cent. of the issued share capital of the Company as at the date of admission on 1 February 2021 ("Admission"). Each tranche of options will be subject to a performance condition which must be wholly satisfied for the relevant option to be exercisable. The performance condition for the first tranche of options is that total shareholder return per Share ("TSR") from Admission until the third anniversary of Admission is at least 100 per cent. of the placing price of 134 pence as at Admission (the "Placing Price"). The performance condition for the second tranche of options is that the TSR from Admission until the fifth anniversary of Admission is at least 200 per cent. of the Placing Price.

Options to subscribe for up to 111,940 Shares at nominal value were granted to Suzanne Smith. The options are subject to a performance condition requiring an average annual TSR of 7.5 per cent. to become exercisable in part and an annual average TSR of 10 per cent. to become fully exercisable, in each case measured over a period of 3 years from Admission as against the Placing Price.

Following the CSOP, Unapproved Scheme awards and the Director Options, the Company will have options outstanding over 6,238,651 shares, representing 5.36% of the Company's issued share capital (plus a further 1,667,722 for options granted prior to Admission representing a further 1.43% of the Company's issued share capital).

Further options or share awards made at the discretion of the Company following the date of this announcement are (together with the CSOP, the Unapproved Scheme awards and the Director Options in this announcement but excluding options issued prior to Admission) subject to a cap not exceeding 10 per cent. of the issued share capital of the Company.

Contacts

Supreme plc

Sandy Chadha, Chief Executive Officer

via Vigo Communications

Suzanne Smith, Chief Financial Officer

Grant Thornton (Nominated Adviser)

Tel: +44 (0)20 7383 5100

Philip Secrett/Samantha Harrison/Harrison Clarke/Seamus Fricker

Berenberg (Broker)

Tel: +44 (0)20 3207 7800

Chris Bowman/Mark Whitmore/Jen Clarke/Samuel Parry

Vigo Communications (PR adviser to the Group)

Tel: +44 (0)20 7390 0230

Jeremy Garcia

Antonia Pollock

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Sandy Chadha

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director, Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Supreme plc

b)

 

LEI

 

 

213800DBHCI5WQWECL16

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares

Identification code

GB00BDT89C08

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

5,825,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

e)

 

Date of the transaction

 

 

9 March 2021

f)

 

Place of the transaction

 

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Suzanne Smith

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director, Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Supreme plc

b)

 

LEI

 

 

213800DBHCI5WQWECL16

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares

Identification code

GB00BDT89C08

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

111,940

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

e)

 

Date of the transaction

 

 

9 March 2021

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZGGFRLVGMZM
Date   Source Headline
8th Aug 20227:00 amRNSGrant of performance share awards to a PDMR
25th Jul 20227:00 amRNSDirector Share Purchase
18th Jul 20224:41 pmRNSDirector Share Purchase
12th Jul 20229:30 amRNSHolding(s) in Company
12th Jul 20229:19 amRNSDirector Share Purchase
8th Jul 20225:14 pmRNSHolding(s) in Company
6th Jul 202212:34 pmRNSHolding(s) in Company
5th Jul 202211:05 amRNSSecond Price Monitoring Extn
5th Jul 202211:00 amRNSPrice Monitoring Extension
5th Jul 20227:00 amRNSFinal Results
21st Jun 20227:00 amRNSNotice of Results & Investor Presentation
13th Jun 20227:00 amRNSAcquisition of Liberty Flights Holdings Limited
10th May 20227:00 amRNSSale of McColl's Retail Group
28th Apr 202212:35 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSInvestor Presentation
12th Apr 20229:05 amRNSSecond Price Monitoring Extn
12th Apr 20229:00 amRNSPrice Monitoring Extension
12th Apr 20227:00 amRNSYear End Trading Update
24th Jan 20222:06 pmRNSSecond Price Monitoring Extn
24th Jan 20222:01 pmRNSPrice Monitoring Extension
24th Jan 202211:05 amRNSSecond Price Monitoring Extn
24th Jan 202211:00 amRNSPrice Monitoring Extension
7th Dec 20217:00 amRNSHalf-year Results
30th Nov 202111:30 amRNSInvestor Presentation
18th Oct 20217:07 amRNSTrading Update & Notice of Results
30th Sep 20213:05 pmRNSResults of AGM
31st Aug 20217:00 amRNSAvailability of Annual Report & Notice of AGM
20th Jul 20217:00 amRNSUnaudited Preliminary Results
19th Jul 20217:00 amRNSLaunch of Sealions Vitamin brand
8th Jul 20217:00 amRNSNotice of Results & Investor Presentation
1st Jul 20217:00 amRNSAcquisition of brands of SCI-MX Limited
11th Jun 20217:00 amRNSAcquisition of Vendek Limited
9th Jun 20217:00 amRNSExercise of options and total voting rights
4th May 20217:00 amRNSTrading Update
6th Apr 20219:05 amRNSSecond Price Monitoring Extn
6th Apr 20219:00 amRNSPrice Monitoring Extension
19th Mar 20211:13 pmRNSGrant of Options under 2021 SAYE Scheme
15th Mar 20217:00 amRNSCompletion of McColl’s roll-out
10th Mar 20217:00 amRNSDirector/PDMR Shareholding
1st Mar 20219:00 amRNSPrice Monitoring Extension
2nd Feb 20214:37 pmRNSHolding(s) in Company
1st Feb 20217:00 amRNSAIM Admission & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.